Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ODT Odonate Therapeutics (ODT) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Odonate Therapeutics Stock (NASDAQ:ODT) 30 days 90 days 365 days Advanced Chart Ad Chaikin AnalyticsNew September Stock WarningSeptember is the most volatile month of the year for stocks. And after the brutal tech selloff, one Wall Street veteran, who served more than 50 years alongside the likes of Paul Tudor Jones and George Soros, just announced: "This is only the beginning."To hear the name and ticker of this doomed AI stock, 100% free, click here. Get Odonate Therapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day Range$1.03▼$1.5552-Week Range N/AVolume87,682 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewOdonate Therapeutics is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Our initial focus is on the development of tesetaxel, a novel chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Tesetaxel has several potential therapeutic advantages over currently available taxanes, including: oral administration with a low pill burden and a patient-friendly dosing regimen; a formulation that does not contain solubilizing agents that are known to cause hypersensitivity (allergic) reactions; and improved activity against chemotherapy-resistant tumors. Tesetaxel has been generally well tolerated in clinical studies and has demonstrated robust single-agent antitumor activity in two Phase 2 studies in patients with locally advanced or metastatic breast cancer (''MBC'').Read More… New September Stock Warning (Ad)September is the most volatile month of the year for stocks. And after the brutal tech selloff, one Wall Street veteran, who served more than 50 years alongside the likes of Paul Tudor Jones and George Soros, just announced: "This is only the beginning."To hear the name and ticker of this doomed AI stock, 100% free, click here. Receive ODT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Odonate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ODT Stock News HeadlinesOdonate Inc ODTCJuly 28, 2024 | morningstar.comProQR Therapeutics NV (PRQR)February 6, 2024 | investing.comNew September Stock WarningSeptember is the most volatile month of the year for stocks. And after the brutal tech selloff, one Wall Street veteran, who served more than 50 years alongside the likes of Paul Tudor Jones and George Soros, just announced: "This is only the beginning."October 7, 2024 | Chaikin Analytics (Ad)Orally Disintegrating Tablet (ODT) Market 2023 | Future Exploration by 2030March 29, 2023 | marketwatch.comPfizer recalls migraine drug Nurtec ODT after millions of products lacked child resistant packagingMarch 19, 2023 | usatoday.comFate Therapeutics Stock (NASDAQ:FATE), Analyst Ratings, Price Targets, PredictionsMarch 3, 2023 | benzinga.comOrally Disintegrating Tablet (ODT) Market Size 2023 with Big Company Segment, Cost-Effective Solutions Analysis Information 2029January 31, 2023 | marketwatch.comODTC Odonate Therapeutics, Inc.October 22, 2022 | seekingalpha.comSee More Headlines ODT Stock Analysis - Frequently Asked Questions How were Odonate Therapeutics' earnings last quarter? Odonate Therapeutics, Inc. (NASDAQ:ODT) announced its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.37) earnings per share for the quarter, missing analysts' consensus estimates of ($0.04) by $0.33. When did Odonate Therapeutics IPO? Odonate Therapeutics (ODT) raised $150 million in an IPO on Thursday, December 7th 2017. The company issued 5,900,000 shares at a price of $24.00-$27.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and Cowen was co-manager. What other stocks do shareholders of Odonate Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Odonate Therapeutics investors own include Exelixis (EXEL), Boeing (BA), Bausch Health Companies (BHC), Fate Therapeutics (FATE), Viking Therapeutics (VKTX), AbbVie (ABBV) and Apellis Pharmaceuticals (APLS). Company Calendar Last Earnings11/10/2021Today10/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ODT CUSIPN/A CIK1717452 Webwww.odonate.com Phone(858) 731-8180FaxN/AEmployees145Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares28,530,000Free Float14,578,000Market CapN/A OptionableNot Optionable BetaN/A Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:ODT) was last updated on 10/7/2024 by MarketBeat.com Staff From Our PartnersCRUSHED: How Biden's Replacement Will Devastate Your 401(k)!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a ...Golden Crest | SponsoredWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adopti...Porter & Company | SponsoredStrikes and Economic Unrest: Are You Prepared for What’s Coming?The rapid advancement of artificial intelligence and automation is reshaping industries and posing threats to ...InvestorPlace | SponsoredWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredNew September Stock WarningSeptember is the most volatile month of the year for stocks. And after the brutal tech selloff, one Wall St...Chaikin Analytics | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredAI Detects Profit Surge On MondayThis has given investors the opportunity to beat the market by 1,700% and a 100% win rate to begin the year.Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Odonate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Odonate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.